Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
ORLANDO, FL / ACCESSWIRE / November 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed a supplier agreement with market leading kinesiology tape company, KT Tape. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer for a new line of specialized KT tape.
佛罗里达州奥兰多/ACCESSWIRE/2023年11月8日/Nutriband Inc.(纳斯达克股票代码:NTRB)(纳斯达克股票代码:NTRBW)今天宣布,它已与市场领先的肌内效胶带公司KT Tape签署了供应商协议。Nutriband Inc. '其全资合同制造子公司Active Intelligence将担任新系列专业KT磁带的制造商。
Founded in 2008, KT Tape has revolutionized the sports medicine industry with the introduction of the most advanced and recognized kinesiology tape and recovery products in the world. KT Tape is recognized as a leader in sports-related drug-free pain and injury treatment. The mission of the company is to develop breakthrough solutions to help enable athletes and fitness enthusiasts to perform at their best. KT Tape is currently available in over 40,000 stores in the US and across the world. KT is also widely used by many major sports franchises throughout the US.
KT Tape 成立于 2008 年 通过引入世界上最先进、最受认可的肌内效学胶带和恢复产品,彻底改变了运动医学行业。KT Tape被公认为运动相关无药物疼痛和损伤治疗领域的领导者。该公司的使命是开发突破性的解决方案,帮助运动员和健身爱好者发挥最佳表现。KT Tape目前在美国和世界各地的40,000多家商店有售。KT还被美国许多主要体育特许经营权广泛使用。
"This supplier agreement with KT Tape allows Nutriband and our contract manufacturing subsidiary, Active Intelligence, to showcase our capabilities in the development and manufacturing of innovative new product technologies with one of the world's largest brands" said Gareth Sheridan, CEO of Nutriband.
Nutriband首席执行官Gareth Sheridan表示:“这份与KT Tape的供应商协议使Nutriband和我们的合同制造子公司Active Intelligence能够展示我们在与全球最大的品牌之一合作开发和制造创新产品技术方面的能力。”
About Nutriband Inc.
关于 Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA technology. Aversa is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.
我们主要从事透皮药物产品组合的开发。我们正在开发的主要产品是一款含有我们的 AVERSA 的防滥用芬太尼补丁 技术。Aversa是一种抑制滥用的透皮技术,它含有厌恶药物,可防止可能被滥用的药物,特别是阿片类药物的滥用、转移、滥用和意外接触。
The Company's website is . Any material contained in or derived from the Company's websites or any other website is not part of this press release.
该公司的网站是。公司网站或任何其他网站中包含或衍生的任何材料均不属于本新闻稿的一部分。
About Our Forward-Looking Statements
关于我们的前瞻性陈述
Certain statements contained in this press release, including, without limitation, statements containing the words ''believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an under capitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2022 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
本新闻稿中包含的某些陈述,包括但不限于包含 “相信”、“预期”、“期望” 等词语和类似含义的言论,构成1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。此类前瞻性陈述涉及已知和未知的风险和不确定性。公司的实际业绩可能与其前瞻性陈述中的预期存在重大差异,这要归因于多种因素,包括公司开发其拟议的滥用威慑芬太尼透皮系统和其他拟议产品的能力、其滥用技术获得专利保护的能力、获得开发产品和进行必要临床测试所需的融资的能力、获得联邦食品药品监督管理局批准销售其任何产品的能力可能会发展在美国并获得在其他国家(包括欧洲国家)销售任何产品所必需的任何其他监管部门批准,其销售可能开发的任何产品的能力,创造、维持、管理或预测其增长的能力;吸引和留住关键人员的能力;公司业务战略或发展计划的变化;竞争;业务中断;负面影响以及国际、国家和地方总体经济和市场状况以及通常与资本不足相关的风险化开发公司,以及公司截至2022年1月31日止年度的S-1表格、10-K表格和10-Q表中 “风险因素” 和 “管理层对财务状况和经营业绩的讨论与分析” 以及公司向美国证券交易委员会提交的其他文件中包含的风险。除非适用法律要求,否则我们没有义务修改或更新任何前瞻性陈述以反映本文发布之日后可能发生的任何事件或情况。
For more information, contact:
欲了解更多信息,请联系:
Patrick Ryan
CTO Nutriband Inc
paddyr@nutriband.com / support@nutriband.com
121 S Orange Ave, Orlando, FL, 32407
+1 (407) 377-6695
帕特里克·瑞
首席技术官 Nutriband Inc
paddyr@nutriband.com/support@nutriband.com
佛罗里达州奥兰多市南奥兰治大道 121 号,32407
+1 (407) 377-6695
SOURCE: Nutriband Inc.
来源:Nutriband Inc.